DOCSLIB.ORG

Overcoming Inhibitor Resistance in the Shv Βeta

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Overcoming Inhibitor Resistance in the Shv Βeta OVERCOMING INHIBITOR RESISTANCE IN THE SHV ΒETA-LACTAMASE By JODI MICHELLE THOMSON Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Dissertation Advisor: Robert A Bonomo Department of Pharmacology CASE WESTERN RESERVE UNIVERSITY August, 2007 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of ______________________________________________________ candidate for the Ph.D. degree *. (signed)_______________________________________________ (chair of the committee) ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ ________________________________________________ (date) _______________________ *We also certify that written approval has been obtained for any proprietary material contained therein. For Robert A. Bonomo TABLE OF CONTENTS Table of Contents ............................................................................... 1-2 List of Figures ..................................................................................... 3-8 List of Tables...........................................................................................9 Acknowledgments........................................................................... 10-12 Abbreviations .................................................................................. 13-14 Abstract........................................................................................... 15-16 Chapter 1: Introduction ................................................................... 17-43 Body......................................................................................... 17-31 Figures ..................................................................................... 32-43 Chapter II: SHV Arg244: Clavulanate Resistance.......................... 44-81 Introduction .............................................................................. 44-46 Methods ................................................................................... 47-58 Results ..................................................................................... 59-64 Discussion................................................................................ 65-69 Tables ...................................................................................... 70-72 Figures ..................................................................................... 73-81 Chapter III: Arg 244: Sulbactam Susceptibility ............................. 82-108 Introduction .............................................................................. 82-85 Methods ................................................................................... 86-88 Results ..................................................................................... 89-92 1 Discussion................................................................................ 93-98 Tables .................................................................................... 99-101 Figures ................................................................................. 102-108 Chapter IV: Inhibition of SHV ESBLs by Transition State Analogs ....................................................................... 109-121 Introduction .......................................................................... 109-111 Methods ............................................................................... 112-113 Results ................................................................................. 114-115 Discussion............................................................................ 116-117 Tables ..........................................................................................118 Figures ................................................................................. 119-121 Chapter V: β-Lactamase Inhibition by BLIP ............................... 122-146 Introduction .......................................................................... 122-125 Methods ............................................................................... 126-130 Results ................................................................................. 131-133 Discussion............................................................................ 134-137 Tables .................................................................................. 138-139 Figures ................................................................................. 140-146 Chapter VI: Concluding Remarks............................................... 147-154 Bibliography ................................................................................ 155-171 2 LIST OF FIGURES 1-1 Examples of the 8 generations of β-lactam antibiotics currently on the market exemplify conservation of the lactam backbone and diversity of the side-chains 1-2 The mechanism of attachment of the penicillin binding protein (PBP) to its natural D-Ala D-Ala substrate (top) and a β-lactam antibiotic (bottom) is strikingly similar 1-3 The crystal structure of SHV β-lactamase (Protein Data Bank accession number 1SHV) 1-4 The SHV β-lactamase active site pocket, highlighting important residues for catalysis and substrate specificity 1-5 The numbering scheme for the backbone nucleus of penicillins and cephalosporins 1-6 Structures of the β-lactamase inhibitors currently on the market. The main difference between these and the beta-lactam antibiotics is the presence of a good leaving group at the 1 position 1-7 The pathway of inhibition by clavulanate in the active site of class A β- lactamases is a multi-step process with numerous intermediates 1-8 The proposed contribution of Arg244 to clavulanate inactivation of TEM-1: (A) Direct hydrogen bonding interactions (B) Coordination of a catalytic water molecule essential for inactivation 3 1-9 Structures of cephalosporins and corresponding boronic acid transition state inhibitors (BATSIs): (A) Ceftazidime (B) Ceftazidime BATSI (C) Cefotaxime (D) Cefotaxime BATSI (E) Cephalothin (F) Achiral Cephalothin BATSI (G) Chiral Cephalothin BATSI 1-10 Chemical structure of novel penem inhibitors(1 and 2) developed by Wyeth Pharmaceuticals which display large, bicyclic R1 side chains 1-11 Endo-trig cyclization of Penem 1 in the active site of a β-lactamase results in the formation of a seven-membered ring 1-12 The results of alanine scanning mutagenesis of BLIP indicated fewer “hotspots” of BLIP binding to SHV-1 (left) compared to TEM-1 (right). Residues identified as critical for binding are in red (reduce binding >10 fold when mutated), residues that, when mutated, lead to an increase in affinity are colored cyan, and residues that had a < 10 fold effect on affinity when mutated are colored green. (Zhang and Palzkill, JBC 279-41, 42860-42866) 2-1 Chemical structures of compounds tested in this study. The structures of clavulanic acid and nitrocefin are labeled with the accepted ring numbering system 2-2 The proposed contribution of Arg244 to clavulanic acid inactivation of TEM-1. The guanidinium group of Arg244 is essential for (A) hydrogen bonding interactions with the C3 carboxylate of the inhibitor in the active site, and (B) coordination of a proton donating water molecule essential for the saturation of the double bond of the C2 constituent (Imtiaz et al., 1993) 4 2-3 Synthesis of the chiral cephalothin boronic acid transition state inhibitor (A) (+)-Pinanediol, THF, rt; (B) (dichloromethyl)lithium, THF, –100 °C → 0 °C; (C) lithium bis(trimethylsilyl)amide, THF, –80 °C → rt; (D) 2-thiopheneacetylchloride, 2- thiopheneacetic acid, THF –80 → rt; (E) aqueous HCl 3N, 1h, 100 °C 2-4 Timed inactivation of SHV-1 and Arg244Ser, -Gln, -Leu, and –Glu reveal that Arg244 variants are inactivated more rapidly by clavulanate than SHV-1. Enzymes were incubated with KI concentrations of clavulanate and initial velocities of nitrocefin hydrolysis measured at timepoints 0-600 seconds 2-5 (A) Deconvoluted mass spectra of SHV-1 and Arg244Ser before and after 15- minute incubation with clavulanate show similar intermediates of inactivation. Spectra were obtained on a Q-STAR XL quadrupole-time-of-flight mass spectrometer equipped with a nanospray source. Eight distinct mass shifts were identified with both enzymes. (B) Proposed intermediates in the clavulanate inactivation pathway. The 198 Da and 173 Da adducts are represented by more than one candidate structure (blue). The terminally inactivated 52 Da crosslinked species is highlighted in red 2-6 The time-dependent inhibition of the chiral cephalothin boronic acid transition state inhibitor (compound 2) is more significant with SHV-1 than with SHV Arg244 Ser, -Gln, -Leu, and -Glu. Enzymes were incubated with inhibitor at concentrations equal to the Ki and initial velocities of nitrocefin hydrolysis assessed at 0-3600s. Initial Ki determination was performed after a 5 minute incubation 5 2-7 Arg244 in relation to Val216 in the SHV-1 (1SHV) and TEM-1 (1BTL) in apo- enzyme crystal structure representations. The distance between the backbone carbonyl oxygen of Val216 and the nearest guanidinium nitrogen in SHV is 7.85 Å. In contrast, the distance in TEM-1 is 5.19 Å. Shown in TEM-1 is the bridging water molecule which makes hydrogen bonds with Val216 (2.87 Å) and Arg244 (3.08 Å). The active site Ser70 is shown for reference 2-8 Suggested role of Arg 244 in stabilizing the β-lactam carboxylate of penicillins, cephalosporins,
Load more

Recommended publications
  • Killing of Gram-Negative Bacteria by Lactoferrin and Lysozyme
    Killing of gram-negative bacteria by lactoferrin and lysozyme. R T Ellison 3rd, T J Giehl J Clin Invest. 1991;88(4):1080-1091. https://doi.org/10.1172/JCI115407. Research Article Although lactoferrin has antimicrobial activity, its mechanism of action is not full defined. Recently we have shown that the protein alters the Gram-negative outer membrane. As this membrane protects Gram-negative cells from lysozyme, we have studied whether lactoferrin's membrane effect could enhance the antibacterial activity of lysozyme. We have found that while each protein alone is bacteriostatic, together they can be bactericidal for strains of V. cholerae, S. typhimurium, and E. coli. The bactericidal effect is dose dependent, blocked by iron saturation of lactoferrin, and inhibited by high calcium levels, although lactoferrin does not chelate calcium. Using differing media, the effect of lactoferrin and lysozyme can be partially or completely inhibited; the degree of inhibition correlating with media osmolarity. Transmission electron microscopy shows that E. coli cells exposed to lactoferrin and lysozyme at 40 mOsm become enlarged and hypodense, suggesting killing through osmotic damage. Dialysis chamber studies indicate that bacterial killing requires direct contact with lactoferrin, and work with purified LPS suggests that this relates to direct LPS-binding by the protein. As lactoferrin and lysozyme are present together in high levels in mucosal secretions and neutrophil granules, it is probable that their interaction contributes to host defense. Find the latest version: https://jci.me/115407/pdf Killing of Gram-negative Bacteria by Lactofernn and Lysozyme Richard T. Ellison III*" and Theodore J. Giehl *Medical and tResearch Services, Department of Veterans Affairs Medical Center, and Division ofInfectious Diseases, Department ofMedicine, University ofColorado School ofMedicine, Denver, Colorado 80220 Abstract (4).
    [Show full text]
  • Of Penicillin G, Other Penicillins, and a Cephalosporin
    GLYCOPEPTIDE TRANSPEPTIDASE AND D-ALANINE CARBOXYPEPTIDASE: PENICILLIN-SENSITIVE ENZYMATIC REACTIONS* BY KAZUO IZAKI, M\ICHIO M\ATSUHASHI, AND JACK L. STROMINGER DEPARTMENT OF PHARMACOLOGY, UNIVERSITY OF WISCONSIN MEDICAL SCHOOL, MADISON Communicated by Clinton L. Woolsey, January 28, 1966 In 1929, Fleming discovered penicillins and observed that this group of substances kills gram-positive bacteria more effectively than gram-negative bacteria (thus im- plying some important physiological difference between the two groups of or- ganisms).1 Subsequent knowledge of the bacterial cell wall made it possible to establish both on physiological and chemical grounds that penicillins are specific and highly selective inhibitors of the biosynthesis of cell walls, both in gram-positive and in gram-negative bacteria.2-6 The reason for the relative insensitivity of gram- negative bacteria to most penicillins has remained obscure. More recent knowledge of the structure and biosynthesis of bacterial cell walls has suggested that, in a terminal reaction in cell wall synthesis, linear glycopeptide strands are cross-linked in a transpeptidation, accompanied by release of the termi- nal D-alanine of the pentapeptide precursor, with formation of a two- or three- dimensional network. Direct chemical analyses of cell walls prepared from cells treated with penicillin7' 8 and isotopic studies of wall biosynthesis9' 10 suggested that penicillin was interfering with this hypothetical glycopeptide cross-linking reaction. In the presence of penicillin, nascent glycopeptide,
    [Show full text]
  • CARBAPENEMASE PRODUCING Enterobacteriaceae: MOLECULAR EPIDEMIOLOGY and ASSESSMENT of ALTERNATIVE THERAPEUTIC OPTIONS
    CARBAPENEMASE PRODUCING Enterobacteriaceae: MOLECULAR EPIDEMIOLOGY AND ASSESSMENT OF ALTERNATIVE THERAPEUTIC OPTIONS By LAURA JIMENA ROJAS COY Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Microbiology and Molecular Biology CASE WESTERN RESERVE UNIVERSITY May, 2018 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of Laura Jimena Rojas Coy candidate for the degree of Doctor of Philosophy*. Committee Chair Dr. Arne Riestch Committee Member Dr. Liem Nguyen Committee Member Dr. Anthony Wynshaw-Boris Committee Member Dr. Robert A. Bonomo Date of Defense March 22, 2018 *We also certify that written approval has been obtained for any proprietary material contained therein. DEDICATION To my mother Maria Grelly and my father Daniel for raising me believing that with hard work I could achieve anything I set my mind to. To my loving brother Cami for constantly looking up to me, inspiring me to always do my best; and finally to my adorable little sister Angie for her infinite an unconditional love. I love you all so much. iii ACKNOWLEDGEMENTS My deepest gratitude and appreciation to my mentor, Dr. Robert A. Bonomo, for being so generous, understanding and patient and for giving me so many wonderful opportunities, in spite of not following the "traditional" path. In addition to the tremendous academic support, he has shown me by his example that humbleness, fairness and leadership is what truly makes a good scientist. To my committee members thank you for your valuable suggestions and criticisms. To everyone in the Bonomo Lab, thank you for sharing your expertise with me and, for constantly helping me, and for each and every one of your invaluable contributions to the work summarized in this dissertation.
    [Show full text]
  • SUPPLEMENTARY MATERIAL 1 /FODOR ET AL Zoonic and Veterinary Pathogen Candidates for the “ESCAPE Club” S1.1 Escherichia Coli Commensal Strains of E
    SUPPLEMENTARY MATERIAL 1 /FODOR ET AL Zoonic and veterinary pathogen candidates for the “ESCAPE Club” S1.1 Escherichia coli Commensal strains of E. coli, as versatile residents of the lower intestine, are also repeatedly challenged by antimicrobial pressures during the lifetime of their host. Consequently, commensal strains acquire resistance genes, and/or develop resistant mutants in order to survive and maintain microbial homeostasis in the lower intestinal tract. Commensal E. coli strains are regarded as indicators of the antimicrobial load of their hosts. The recent review (Szmolka, A. and Nagy, B. 2013) described the historical background of the origin, appearance and transfer mechanisms of antimicrobial resistance genes into an original animal - commensal intestinal E. coli with comparative information on their pathogenic counterparts. The most efficient mechanism used by E. coli against different antimicrobial-based efflux pumps and mobile resistance mechanisms carried by plasmids and/or mobile genetic elements is known. For a while, these mechanisms cannot protect E. coli against fabclavine (Fodor L. et al., in preparation). The emergence of hybrid plasmids, both resistance and virulent, among E. coli is of additional public concern. Co-existence and co-transfer of these “bad genes” in this huge and most versatile in vivo compartment may represent increased public health risk in the future. The significance of MDR commensal E. coli seems to be highest in the food animal industry, which may function as a reservoir for intra- and interspecific exchange, and a source for the spread of MDR determinants through contaminated food to humans. Thus, the potential of MDR occurring in these commensal bacteria living in animals used as sources of food (as meat, eggs, milk) should be a concern from the aspect of public health, and it needs to be continuously monitored in the future by using the toolkit of molecular genetics [8].
    [Show full text]
  • Evolution of Vancomycin-Resistant Enterococcus Faecium During Colonization and Infection in Immunocompromised Pediatric Patients
    Evolution of vancomycin-resistant Enterococcus faecium during colonization and infection in immunocompromised pediatric patients Gayatri Shankar Chilambia, Hayley R. Nordstroma, Daniel R. Evansa, Jose A. Ferrolinob, Randall T. Haydenc, Gabriela M. Marónb,d, Anh N. Vob,d, Michael S. Gilmoree,f, Joshua Wolfb,d,1, Jason W. Roschb,1, and Daria Van Tynea,1,2 aDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213; bDepartment of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105; cDepartment of Pathology, St. Jude Children’s Research Hospital, Memphis, TN 38105; dDepartment of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38105; eDepartment of Ophthalmology, Harvard Medical School and Massachusetts Eye and Ear Infirmary, Boston, MA 02114; and fDepartment of Microbiology, Harvard Medical School, Boston, MA 02115 Edited by Paul E. Turner, Yale University, New Haven, CT, and approved April 8, 2020 (received for review October 13, 2019) Patients with hematological malignancies or undergoing hemato- in the hospital environment poses a major threat to patient poietic stem cell transplantation are vulnerable to colonization safety, and vancomycin-resistant E. faecium (VREfm) carrying and infection with multidrug-resistant organisms, including VanA-type resistance currently pose the biggest threat in the vancomycin-resistant Enterococcus faecium (VREfm). Over a 10-y United States (10–12). period, we collected and sequenced the genomes of 110 VREfm Immunocompromised patients are prone to drug-resistant isolates from gastrointestinal and blood cultures of 24 pediatric enterococcal infection, due to frequent use of broad-spectrum patients undergoing chemotherapy or hematopoietic stem cell antibiotics in hospital environments where resistant lineages transplantation for hematological malignancy at St.
    [Show full text]
  • Genome Sequencing Analysis of Streptomyces Coelicolor Mutants That Overcome the Phosphate-Depending Vancomycin Lethal Effect Fernando Santos-Beneit1,2
    Santos-Beneit BMC Genomics (2018) 19:457 https://doi.org/10.1186/s12864-018-4838-z RESEARCH ARTICLE Open Access Genome sequencing analysis of Streptomyces coelicolor mutants that overcome the phosphate-depending vancomycin lethal effect Fernando Santos-Beneit1,2 Abstract Background: Glycopeptide antibiotics inhibit bacterial cell-wall synthesis, and are important for the treatment of infections caused by multi drug-resistant strains of enterococci, streptococci and staphylococci. The main mechanism by which bacteria resist the action of glycopeptides is by producing a modified cell-wall in which the dipeptide D-Alanine-D-Alanine is substituted by D-Alanine-D-Lactate or D-Alanine-D-Serine. Recently, it has been shown that inorganic phosphate (Pi) induces hypersensitivity to vancomycin in Streptomyces coelicolor (which is highly resistant to the antibiotic in low-Pi media). This finding was surprising because the bacterium possesses the entire set of genes responsible for vancomycin resistance (VR); including those coding for the histidine kinase/response regulator pair VanS/VanR that activates the system. Results: This work shows that high Pi amounts in the medium hamper the activation of the van promoters and consequently inhibit VR in S. coelicolor; i.e. the repression effect being stronger when basic or acidic forms of the nutrient are used. In addition, this work shows that lysozyme resistance is also highly regulated by the Pi concentration in the medium. At least five different mutations contribute to the overcoming of this repression effect over VR (but not over lysozyme resistance). Therefore, the interconnection of VR and lysozyme resistance mechanisms might be inexistent or complex.
    [Show full text]
  • Polymyxins and Their Potential Next Generation As Therapeutic Antibiotics
    fmicb-10-01689 September 30, 2019 Time: 18:27 # 1 View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Helsingin yliopiston digitaalinen arkisto PERSPECTIVE published: 25 July 2019 doi: 10.3389/fmicb.2019.01689 Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics Martti Vaara1,2* 1 Northern Antibiotics Ltd., Espoo, Finland, 2 Department of Bacteriology and Immunology, Helsinki University Medical School, Helsinki, Finland The discovery of polymyxins, highly basic lipodecapeptides, was published independently by three laboratories in 1947. Their clinical use, however, was abandoned in the sixties because of nephrotoxicity and because better-tolerated drugs belonging to other antibiotic classes were discovered. Now polymyxins have resurged as the last- resort drugs against extremely multi-resistant strains, even though their nephrotoxicity forces clinicians to administer them at doses that are lower than those required for optimal efficacy. As their therapeutic windows are very narrow, the use of polymyxins has received lots of justified criticism. To address this criticism, consensus guidelines for the optimal use of polymyxins have just been published. Quite obviously, too, improved polymyxins with increased efficacy and lowered nephrotoxicity would be more than welcome. Over the last few years, more than USD 40 million of public money has been used in programs that aim at the design of novel polymyxin derivatives. This Edited by: perspective article points out that polymyxins do have potential for further development Aixin Yan, and that the novel derivatives already now at hand might offer major advantages over The University of Hong Kong, Hong Kong the old polymyxins.
    [Show full text]
  • Penicillin and Serendipity
    Penicillin and Serendipity Tony White [email protected]© by author ESCMID Online Lecture Library International Day of Fighting Infection, 23 April 2012 Penicillin: a captivating story 1952 1946 1962 1980 © by author 1975 2004 2007 ESCMID Online Lecture Library Penicillin and Serendipity SERENDIPITY “The faculty of making happy and unexpected discoveries by accident” -from Horace Walpole (1754) after The Princes of Serendip (Oxford Concise Dictionary) PENICILLIN happy and unexpected© discovery? by author an accident? Was the penicillin story a series of lucky events? ESCMID Online Lecture Library The ‘Eureka’ moment and beyond…..? The result of a surprise ‘happy and unexpected discovery’ by accident? …or… The result of painstaking research, study, experiment and observation with foresight and belief? A discovery by a maverick individual with a singular vision who discovers what thay have been seeking (against disbelief, ridicule, adversity) …or… The result of dedicated and focussed teams working towards clear targets and objectives © by author “It is the individual human, working out his own design of life who gives the world what progress it has made” Alexander Fleming ESCMID Online Lecture Library “Science is the graveyard of ideas” Pasteur leading to Something with limited application, known only to few and can’t be developed, made available or used …or… Something needed, developed, usable , known and available It is only those with a value and use which we are able to look back on today in the context of their role
    [Show full text]
  • Transcriptome-Based Design of Antisense Inhibitors Re-Sensitizes CRE E
    bioRxiv preprint doi: https://doi.org/10.1101/2019.12.16.878389; this version posted December 17, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Transcriptome-based design of antisense inhibitors re-sensitizes CRE E. coli to 2 carbapenems 3 Thomas R. Aunins1,#, Keesha E. Erickson1,#, and Anushree Chatterjee1,2,3* 4 #These authors contributed equally 5 *Corresponding author: Email: [email protected]. Phone: (303) 735-6586, Fax: (303) 492- 6 8424 7 8 1Department of Chemical and Biological Engineering, University of Colorado Boulder, Boulder 9 Colorado, USA 10 2Biomedical Engineering Program, University of Colorado Boulder, USA. 11 3Antimicrobial Regeneration Consortium, Boulder, USA. 1 bioRxiv preprint doi: https://doi.org/10.1101/2019.12.16.878389; this version posted December 17, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 12 Abstract 13 Carbapenems are a powerful class of antibiotics, often used as a last-resort treatment to eradicate 14 multidrug-resistant infections. In recent years, however, the incidence of carbapenem-resistant 15 Enterobacteriaceae (CRE) has risen substantially, and the study of bacterial resistance 16 mechanisms has become increasingly important for antibiotic development. Although much 17 research has focused on genomic contributors to carbapenem resistance, relatively few studies 18 have examined CRE pathogens through changes in gene expression. In this research, we used 19 transcriptomics to study a CRE Escherichia coli clinical isolate that is sensitive to meropenem but 20 resistant to ertapenem, to both explore carbapenem resistance and identify novel gene 21 knockdown targets for carbapenem re-sensitization.
    [Show full text]
  • Structural Characterization of Bacterial Defense Complex Marko Nedeljković
    Structural characterization of bacterial defense complex Marko Nedeljković To cite this version: Marko Nedeljković. Structural characterization of bacterial defense complex. Biomolecules [q-bio.BM]. Université Grenoble Alpes, 2017. English. NNT : 2017GREAV067. tel-03085778 HAL Id: tel-03085778 https://tel.archives-ouvertes.fr/tel-03085778 Submitted on 22 Dec 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE Pour obtenir le grade de DOCTEUR DE LA COMMUNAUTE UNIVERSITE GRENOBLE ALPES Spécialité : Biologie Structurale et Nanobiologie Arrêté ministériel : 25 mai 2016 Présentée par Marko NEDELJKOVIĆ Thèse dirigée par Andréa DESSEN préparée au sein du Laboratoire Institut de Biologie Structurale dans l'École Doctorale Chimie et Sciences du Vivant Caractérisation structurale d'un complexe de défense bactérienne Structural characterization of a bacterial defense complex Thèse soutenue publiquement le 21 décembre 2017, devant le jury composé de : Monsieur Herman VAN TILBEURGH Professeur, Université Paris Sud, Rapporteur Monsieur Laurent TERRADOT Directeur de Recherche, Institut de Biologie et Chimie des Protéines, Rapporteur Monsieur Patrice GOUET Professeur, Université Lyon 1, Président Madame Montserrat SOLER-LOPEZ Chargé de Recherche, European Synchrotron Radiation Facility, Examinateur Madame Andréa DESSEN Directeur de Recherche, Institut de Biologie Structurale , Directeur de These 2 Contents ABBREVIATIONS ..............................................................................................................................
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Enhancement of Penicillin-Induced Lysis in <I>Sarcina Lutea</I>
    555 Journal of Food Protection Vol 40, No. 8, Pages 555-557 (,4ugust, 1977) Copyright © 1977, International Association of Milk, Food, and Environmental Sanitarians Enhancement of Penicillin-Induced Lysis in Sarcina lutea by Lysozyme JOSEPH M. KORNFELD Laboratory Division, Connecticut State Department ofHealth. Hartford, Connecticut06101 Downloaded from http://meridian.allenpress.com/jfp/article-pdf/40/8/555/1649545/0362-028x-40_8_555.pdf by guest on 26 September 2021 (Received for publication January 21, 1977) ABSTRACT penicillin are detected when lysozyme is added to the Using either paper disc or cylinder plate methods for detection of detection system. penicillin, addition of egg-white lysozme (N-acetylmuramide glycano­ hydrolase, E. C. 3.2.1.17) to seeded agar caused production of larger MATERIALS AND METHODS zones of inhibition. The increased zone size enables detection of lesser The procedures used were modified from the established protocols for quantities of the antibiotic. It is suggested that this modification be the assay of penicillin in various materials (2). Antibiotic Agar #4 (BBL) considered for use in detection of low levels of the antibiotic. in 100-ml volumes was seeded with 0.03 ml of a suspension of S. lutea (ATCC 9341) prepared by washing the surface of an overnight slant Under regulations of the United States Food and Drug culture with 5 ml of physiological saline. The seeded agar was agitated to ensure homogeneity and maintained at 49 C for not more than 30 Administration (FDA), presence of penicillin in milk min before use. Freshly prepared lysozyme solution (Egg white, Sigma, constitutes adulteration. Since the current FDA regula­ 3x crystallized) in phosphate buffer, pH 6.0 was added to 100 x 15 mm tions specify a zero-tolerance for the antibiotic in milk plastic petri plates and the total volume adjusted to 1 ml with and milk products (4), it follows that any milk which additional buffer.
    [Show full text]